What question did this study set out to answer?

This trial aims to evaluate the efficacy and safety of JNJ-67484703, a PD-1 agonist, in treating participants with moderate-to-severe atopic dermatitis.

April 22, 2026Dermatology and TherapyOpen Access

Efficacy and Safety of the PD-1 Agonist JNJ-67484703 in Participants with Atopic Dermatitis: Phase 2a, Randomized, Double-Blind, Placebo-Controlled Trial Results

View Full Paper

Ask AI

Bookmark

Authors

MCMichael CecchiniYale New Haven Hospital BKBartlomiej Kwiek FLFang Liu-WalshJohnson & Johnson (United States)

Discussion

Member takes

Implication

Phase 2a trial demonstrates JNJ-67484703 efficacy in improving symptoms of atopic dermatitis, suggesting further exploration is needed.

Key Points

This trial aims to evaluate the efficacy and safety of JNJ-67484703, a PD-1 agonist, in treating participants with moderate-to-severe atopic dermatitis.
Phase 2a double-blind placebo-controlled design
Participants with EASI score ≥ 16 randomized to JNJ-67484703 or placebo for 12 weeks
Primary endpoint assessed was the EASI-75 improvement at week 12.
25% of participants receiving JNJ-67484703 achieved EASI-75 compared to 11.8% on placebo, with a P-value of 0.4590.
The percentage improvement in EASI score was -41.0% for JNJ-67484703 versus -20.8% for placebo.
Adverse events were similar between groups, with 88.2% for JNJ-67484703 and 82.4% for placebo.

Cite This Study

Cecchini et al. (2026) studied this question.

synapsesocial.com/papers/69e865b56e0dea528ddea2de https://doi.org/10.1007/s13555-026-01746-6

View Full Paper

Ask AI

Bookmark

April 22, 2026Dermatology and TherapyOpen Access

Efficacy and Safety of the PD-1 Agonist JNJ-67484703 in Participants with Atopic Dermatitis: Phase 2a, Randomized, Double-Blind, Placebo-Controlled Trial Results

View Full Paper

Ask AI

Bookmark

Authors

MCMichael CecchiniYale New Haven Hospital BKBartlomiej Kwiek FLFang Liu-WalshJohnson & Johnson (United States)

Discussion

Member takes

Implication

Phase 2a trial demonstrates JNJ-67484703 efficacy in improving symptoms of atopic dermatitis, suggesting further exploration is needed.

Key Points

This trial aims to evaluate the efficacy and safety of JNJ-67484703, a PD-1 agonist, in treating participants with moderate-to-severe atopic dermatitis.
Phase 2a double-blind placebo-controlled design
Participants with EASI score ≥ 16 randomized to JNJ-67484703 or placebo for 12 weeks
Primary endpoint assessed was the EASI-75 improvement at week 12.
25% of participants receiving JNJ-67484703 achieved EASI-75 compared to 11.8% on placebo, with a P-value of 0.4590.
The percentage improvement in EASI score was -41.0% for JNJ-67484703 versus -20.8% for placebo.
Adverse events were similar between groups, with 88.2% for JNJ-67484703 and 82.4% for placebo.

Cite This Study

Cecchini et al. (2026) studied this question.

synapsesocial.com/papers/69e865b56e0dea528ddea2de https://doi.org/10.1007/s13555-026-01746-6

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark